Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses KURA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KURA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Troy Wilson | $700,000 | $0 | $0 | $3,297,250 | $630,000 | $0 | $107,766 | $4,735,016 |
| Chairman, President and Chief Executive Officer | ||||||||
| Brian Powl | 506,348 | 0 | 1,366,247 | 487,993 | 291,150 | 0 | 17,500 | 2,669,238 |
| Chief Commercial Officer | ||||||||
| Kathleen Ford | 539,935 | 0 | 0 | 975,986 | 310,463 | 0 | 76,103 | 1,902,487 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Troy Wilson | $4,735,016 | $6,239,098 | $5,251,407 | −1,504,082 |
| Brian Powl | 2,669,238 | — | — | — |
| Kathleen Ford | 1,902,487 | 2,501,838 | 2,157,853 | −599,351 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Teresa Brophy Bair | Chief Legal Officer | 2026-05-18 | D | 2,256 | $9 | $21,160 | Common, open-market sale | Form 4 ↗ |
| Brian Powl | Chief Commercial Officer | 2026-05-19 | D | 339 | 9 | 3,122 | Common | Form 4 ↗ |
| Kathleen Ford | Chief Operating Officer | 2026-05-19 | D | 2,257 | 9 | 20,483 | Common, open-market sale | Form 4 ↗ |
| Brian Powl | Chief Commercial Officer | 2026-05-21 | D | 10,000 | 11 | 110,000 | Common | Form 4 ↗ |
| Michael Vasconcelles | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Malley | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Faheem Hasnain | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Helen Louise Collins | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol Schafer | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary T. Szela | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diane Parks | Director | 2026-06-04 | A | 35,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mollie Leoni | Chief Medical Officer | 2026-06-18 | D | 84,929 | 10 | 834,283 | Common, open-market sale | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Powl | OTHER | — | — | — | — | — | $1,366,247 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kathleen Ford | PSU | 48,900 | — | $508,071 |
| Troy Wilson | PSU | 182,500 | — | 1,896,175 |
| Brian Powl | RSU | 24,450 | — | 254,036 |
| Troy Wilson | Option | 10,313 | 14.15 | — |
| Brian Powl | RSU | 11,250 | — | 116,888 |
| Troy Wilson | RSU | 182,500 | — | 1,896,175 |
| Brian Powl | Option | 71,303 | 8.68 | — |
| Troy Wilson | Option | 163,334 | 11.99 | — |
| Brian Powl | Option | 15,625 | 15.36 | — |
| Kathleen Ford | Option | 96,355 | 15.36 | — |
| Brian Powl | PSU | 48,900 | — | 508,071 |
| Troy Wilson | Option | 481,771 | 8.68 | — |
| Kathleen Ford | RSU | 48,900 | — | 508,071 |
| Troy Wilson | Option | 291,667 | 15.36 | — |
| Brian Powl | Option | 83,334 | 11.72 | — |
| Kathleen Ford | Option | 142,605 | 8.68 | — |
| Brian Powl | RSU | 46,250 | — | 480,538 |
| Kathleen Ford | RSU | 5,475 | — | 56,885 |
| Kathleen Ford | Option | 53,959 | 11.99 | — |
| Kathleen Ford | Option | 3,563 | 14.15 | — |
Our compensation philosophy is intended to attract and reward talented individuals who possess the skills necessary to expand our business and assist in the achievement of our other strategic goals and thereby create long-term value for our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 48,783,834 | 1,141,854 | 8,755,344 | 97.71% | Passed |
| 2025 | 2025-06-05 | 63,155,796 | 1,522,754 | 91,695 | 97.65% | Passed |
| 2024 | 2024-06-05 | 61,538,693 | 5,449,767 | 111,285 | 91.71% | Passed |
| 2023 | 2023-05-31 | 51,834,962 | 879,497 | 1,398,717 | 95.79% | Passed |
| 2022 | 2022-06-21 | 54,865,869 | 2,211,677 | 28,399 | 96.08% | Passed |
| 2021 | 2021-06-22 | 57,074,798 | 1,744,029 | 7,228 | 97.02% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 97.71%a |
| 2025 | 2025-06-05 | 97.65%b |
| 2024 | 2024-06-05 | 91.71%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will have the effect of votes against this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Faheem HasnainIndependent · Lead Independent Director · Audit · Compensation | $90,215 | $0 | $116,035 | $0 | $0 | $206,250 |
| Mary T. SzelaIndependent · Audit · Compensation (Chair) | 70,215 | 0 | 116,035 | 0 | 0 | 186,250 |
| Carol SchaferIndependent · Audit (Chair) · Nominating/Governance | 70,215 | 0 | 116,035 | 0 | 0 | 186,250 |
| Thomas MalleyIndependent · Audit · Nominating/Governance (Chair) | 65,215 | 0 | 116,035 | 0 | 0 | 181,250 |
| Diane ParksIndependent · Compensation · Nominating/Governance | 57,715 | 0 | 116,035 | 0 | 0 | 173,750 |
| Helen Collins, M.DIndependent · Compensation · Nominating/Governance | 57,715 | 0 | 116,035 | 0 | 0 | 173,750 |
| Michael Vasconcelles, M.DIndependent · Compensation | 52,715 | 0 | 116,035 | 0 | 0 | 168,750 |
| Troy E. Wilson, Ph.D., J.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $116,035 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $464,005 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $464,005 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Kura Oncology, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Kura Oncology, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Summit Therapeutics | 2025 | Mahkam Zanganeh | $616,500 | $0 | $245,021,384 | $0 | $246,047,279 |
| 2 | Cogent Biosciences | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | Revolution Medicines | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 5 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 6 | Crinetics Pharmaceuticals | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 7 | Nuvalent | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 8 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 9 | IDEAYA Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 10 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 11 | Structure Therapeutics | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 12 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 13 | Day One Biopharmaceuticals | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 14 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 15 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 16 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 17 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 18 | Iovance Biotherapeutics | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Crinetics Pharmaceuticals | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Day One Biopharmaceuticals | 123% | Options 50 · RSU 50 | not disclosed | Compensia Inc. |
| IDEAYA Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Iovance Biotherapeutics | 60% | not disclosed | No | Haigh & Company |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Nuvalent | 120% | not disclosed | No | Alpine Rewards |
| Relay Therapeutics | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Revolution Medicines | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon plc (Human Capital Solutions practice) |
| Structure Therapeutics | 125% | Options 67 · RSU 33 | No | Aon |
| Summit Therapeutics | 105% | Options 100 | not disclosed | not disclosed |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Troy Wilson | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Summary Compensation Table for Fiscal”. As printed: 4,735,016. Filing ↗machine: t27 · r2 · c14 · span 1018180–1018189 |
| 2 | Section 01, Brian Powl | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Summary Compensation Table for Fiscal”. As printed: 2,669,238. Filing ↗machine: t27 · r4 · c14 · span 1028878–1028887 |
| 3 | Section 01, Kathleen Ford | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Summary Compensation Table for Fiscal”. As printed: 1,902,487. Filing ↗machine: t27 · r6 · c14 · span 1039416–1039425 |
| 4 | Section 03, Brian Powl OTHER | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE IN FAVOR OF PROPOSAL” · grants of plan-based awards table. Filing ↗machine: t27 · r4 · c6 · span 1026082–1026091 |
| 5 | Section 07, pay ratio | 10-K | 2026-03-05 | 0001193125-26-092567 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 6 | Section 08, Faheem Hasnain | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 206,250. Filing ↗machine: t34 · r3 · c6 · span 1455262–1455269 |
| 7 | Section 08, Mary T. Szela | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 186,250. Filing ↗machine: t34 · r7 · c6 · span 1465268–1465275 |
| 8 | Section 08, Carol Schafer | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 186,250. Filing ↗machine: t34 · r6 · c6 · span 1462766–1462773 |
| 9 | Section 08, Thomas Malley | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 181,250. Filing ↗machine: t34 · r4 · c6 · span 1457764–1457771 |
| 10 | Section 08, Diane Parks | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 173,750. Filing ↗machine: t34 · r5 · c6 · span 1460264–1460271 |
| 11 | Section 08, Helen Collins, M.D | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 173,750. Filing ↗machine: t34 · r2 · c6 · span 1452759–1452766 |
| 12 | Section 08, Michael Vasconcelles, M.D | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 168,750. Filing ↗machine: t34 · r8 · c6 · span 1467786–1467793 |
| 13 | Section 08, Troy E. Wilson, Ph.D., J.D | DEF 14A | 2026-04-10 | 0001193125-26-151335 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 02, Teresa Brophy Bair 2026-05-18 | Form 4 | 2026-05-20 | 0001193125-26-232546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Brian Powl 2026-05-19 | Form 4 | 2026-05-20 | 0001193125-26-232547 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Kathleen Ford 2026-05-19 | Form 4 | 2026-05-20 | 0001193125-26-232548 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Brian Powl 2026-05-21 | Form 4 | 2026-05-22 | 0001193125-26-236838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Michael Vasconcelles 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257902 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Thomas Malley 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257896 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Faheem Hasnain 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257901 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Helen Louise Collins 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257900 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Carol Schafer 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257898 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Mary T. Szela 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257897 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Diane Parks 2026-06-04 | Form 4 | 2026-06-04 | 0001193125-26-257903 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Mollie Leoni 2026-06-18 | Form 4 | 2026-06-22 | 0001193125-26-277780 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001193125-26-257368 | Item 5.07 · say-on-pay result. As reported: 97.71% (votes for as printed: 48,783,834). Filing ↗ |
| 27 | Section 06, 2025 vote | Form 8-K | 2025-06-06 | 0000950170-25-083046 | Item 5.07 · say-on-pay result. As reported: 97.65% (votes for as printed: 63,155,796). Filing ↗ |
| 28 | Section 06, 2024 vote | Form 8-K | 2024-06-07 | 0000950170-24-070584 | Item 5.07 · say-on-pay result. As reported: 91.71% (votes for as printed: 61,538,693). Filing ↗ |
| 29 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 30 | Section 09b board cost (computed) | Computed | — | computed | Cash 464,005 + equity 0 + all other 0 = 464,005, summed across the director compensation table rows.machine: formula: Σ = 464,005 |
| 31 | Summit Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001599298-26-000029 | CEO total compensation as printed in Summit Therapeutics's own proxy. As printed: 246,047,279. Filing ↗machine: r6 · c21 · span 385284–385295 |
| 32 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 33 | SpringWorks Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194 |
| 34 | Revolution Medicines, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines's own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 35 | Janux Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 36 | Crinetics Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals's own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 37 | Nuvalent, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001861560-26-000013 | CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247 |
| 38 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 39 | IDEAYA Biosciences, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 40 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 41 | Structure Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047740 | CEO total compensation as printed in Structure Therapeutics's own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 42 | Syndax Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 43 | Day One Biopharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals's own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 44 | Arvinas, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 45 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 46 | Kura Oncology, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. Filing ↗machine: t27 · r2 · c14 · span 1018180–1018189 |
| 47 | Relay Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 48 | Iovance Biotherapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050458 | CEO total compensation as printed in Iovance Biotherapeutics's own proxy. As printed: 1,888,175. Filing ↗machine: t133 · r6 · c16 · span 797910–797919 |
| 49 | Section 10a, Iovance Biotherapeutics reciprocity | DEF 14A | — | 0001104659-26-050458 | Iovance Biotherapeutics's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 50 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences names Kura Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 51 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 52 | Section 10a, Crinetics Pharmaceuticals reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 53 | Section 10a, Revolution Medicines reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 54 | Section 10a, Syndax Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 55 | Section 10a, Janux Therapeutics reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics names Kura Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 56 | Section 10a, Nuvalent reciprocity | DEF 14A | — | 0001861560-26-000013 | Nuvalent's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 57 | Section 10a, IDEAYA Biosciences reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences names Kura Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 58 | Section 10a, Arvinas reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 59 | Section 10a, Structure Therapeutics reciprocity | DEF 14A | — | 0001104659-26-047740 | Structure Therapeutics's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 60 | Section 10a, Relay Therapeutics reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 61 | Section 10a, SpringWorks Therapeutics reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics's most recent proxy was read; its disclosed peer group does not include Kura Oncology, Inc.. Filing ↗ |
| 62 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor names Kura Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |